Objective: To describe the clinical characteristics, biochemistry, histopathology, and long-term outcomes in subjects with ovotesticular (OT) disorder of sex development (DSD). Study Design: This is a retrospective subset analysis of 64 cases of histologically confirmed OT DSD. Results: All subjects were South African; 97% (n = 62) were African and 92% (n = 59) were of Zulu ethnicity. The most common karyotype was 46,XX (88%; n = 56), followed by 46,XY (8%), 46,XY/45,X (3%), and 46,XX/46,XY (1%). The median age at presentation was 7 months (0.5 months to 5.1 years). Sixty-one of the subjects (95%) presented with DSD. The ovotestis was the most frequent gonad (56%), followed by the ovary (23%) and the testis (16%). Testes were more commonly located on the right and ovaries on the left (p < 0.0001). The male gender was the predominant sex of rearing in two-thirds of the subjects. Gender dysphoria was noted in 8 subjects (11%) at a median of 6.4 (4.3–9.3) years. Long-term follow-up (n = 14) revealed spontaneous puberty in 5 subjects, gender dysphoria in 2 subjects, and neuropsychiatric disorders in 4 subjects. Conclusion: OT DSD is an important differential diagnosis in Black South Africans with 46,XX DSD.

1.
Nistal M, Paniagua R, González-Peramato P, Reyes-Múgica M: Perspectives in pediatric pathology, chapter 7. Ovotesticular DSD (true hermaphroditism). Pediatr Dev Pathol 2015; 18: 345–352.
2.
van Niekerk WA: True hermaphroditism. An analytical review with a report of 3 new cases. Am J Obstet Gynecol 1976;126: 890–907.
3.
Wiersma R, Ramdial PK: The gonads of 111 South African patients with ovotesticular disorder of sex differentiation. J Pediatr Surg 2009;44: 556–560.
4.
Ganie Y, Aldous C, Balakrishna Y, Wiersma R: Disorders of sex development in children in KwaZulu-Natal Durban South Africa: 20-year experience in a tertiary centre. J Pediatr Endocrinol Metab 2017;30: 11–18.
5.
Krstić ZD, Smoljanić Z, Vukanić D, Varinac D, Janjić G: True hermaphroditism: 10 years’ experience. Pediatr Surg Int 2000;16: 580–583.
6.
Wiersma R: True hermaphroditism in Southern Africa: the clinical picture. Pediatr Surg Int 2004;20: 363–368.
7.
Wiersma R: Ovotesticular disorder of sex development in Southern Africa: part 2; thesis, Durban, 2011.
8.
Hadjiathanasiou CG, Brauner R, Lortat-Jacob S, Nivot S, Jaubert F, Fellous M, et al: True hermaphroditism: genetic variants and clinical management. J Pediatr 1994;125(pt 1): 738–744.
9.
Krob G, Braun A, Kuhnle U: True hermaphroditism: geographical distribution, clinical findings, chromosomes and gonadal histology. Eur J Pediatr 1994;153: 2–10.
10.
Verkauskas G, Jaubert F, Lortat-Jacob S, Malan V, Thibaud E, Nihoul-Fékété C: The long-term followup of 33 cases of true hermaphroditism: a 40-year experience with conservative gonadal surgery. J Urol 2007;177: 726–731; discussion 731.
11.
Matsui F, Shimada K, Matsumoto F, Itesako T, Nara K, Ida S, et al: Long-term outcome of ovotesticular disorder of sex development: a single center experience. Int J Urol 2011;18: 231–236.
12.
Sircili MH, Denes FT, Costa EM, Machado MG, Inacio M, Silva RB, et al: Long-term followup of a large cohort of patients with ovotesticular disorder of sex development. J Urol 2014;191(suppl):1532–1536.
13.
Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z: Society for Endocrinology UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development (revised 2015). Clin Endocrinol (Oxford) 2016;84: 771–788.
14.
Kuiri-Hänninen T, Sankilampi U, Dunkel L: Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. Horm Res Paediatr 2014;82: 73–80.
15.
Domenice S, Nishi MY, Billerbeck AE, Car-valho FM, Frade EM, Latronico AC, et al: Molecular analysis of SRY gene in Brazilian 46,XX sex reversed patients: absence of SRY sequence in gonadal tissue. Med Sci Monit 2001;7: 238–241.
16.
Ortenberg J, Oddoux C, Craver R, McElreavey K, Salas-Cortes L, Guillen-Navarro E, et al: SRY gene expression in the ovotestes of XX true hermaphrodites. J Urol 2002;167: 1828–1831.
17.
Tanoue A, Nakamura T, Endo F, Nishiyama S, Sakiyama H, Matsuda I: Sex-determining region Y (SRY) in a patient with 46,XX true hermaphroditism. Jpn J Hum Genet 1992;37: 311–320.
18.
Aaronson IA: True hermaphroditism. A review of 41 cases with observations on testicular histology and function. Br J Urol 1985;57: 775–779.
19.
Mittwoch U: The elusive action of sex-determining genes: mitochondria to the rescue? J Theor Biol 2004;228: 359–365.
20.
Navai N, Erickson BA, Zhao LC, Okotie OT, Gonzalez CM: Complications following urethral reconstructive surgery: a six year experience. Int Braz J Urol 2008;34: 594–600; discussion 601.
21.
Lopez X, Stewart S, Jacobson-Dickman E: Approach to children and adolescents with gender dysphoria. Pediatr Rev 2016; 37: 89–96; quiz 97–98.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.